Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates.
作者信息
Arturo Juan F, Chobrutskiy Boris I, Yeagley Michelle, Patel Dhruv N, Falasiri Shayan, Patel Jay S, Blanck George
机构信息
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, United States.
Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, United States.
出版信息
Cell Mol Immunol. 2020 Jul;17(7):776-778. doi: 10.1038/s41423-019-0328-8. Epub 2019 Nov 15.
Abstract
摘要
相似文献
1
Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates.乳腺癌中B细胞受体互补决定区3（CDR3）与TP53突变氨基酸的静电互补性与无病生存率的提高相关。
Cell Mol Immunol. 2020 Jul;17(7):776-778. doi: 10.1038/s41423-019-0328-8. Epub 2019 Nov 15.
2
Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.T 细胞受体-α CDR3 结构域和突变氨基酸的静电互补性与肉瘤患者的生存率提高相关。
Pediatr Hematol Oncol. 2021 Apr;38(3):251-264. doi: 10.1080/08880018.2020.1843576. Epub 2021 Feb 22.
3
A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.一种用于 T 细胞受体和癌症突变氨基酸静电互补性的评分系统：与相关生存率的多癌症分析。
Immunology. 2020 Apr;159(4):373-383. doi: 10.1111/imm.13165. Epub 2020 Jan 21.
4
High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.高通量、滑动窗口算法评估免疫受体 CDR3 结构域与癌症突变肽之间的化学互补性：TRG-PIK3CA 相互作用和乳腺癌。
Mol Immunol. 2021 Jul;135:247-253. doi: 10.1016/j.molimm.2021.02.026. Epub 2021 Apr 29.
5
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.新辅助化疗后残留疾病中 TP53 和 PIK3CA 的共突变与乳腺癌不良生存相关。
J Cancer Res Clin Oncol. 2019 May;145(5):1235-1242. doi: 10.1007/s00432-019-02873-8. Epub 2019 Feb 26.
6
Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.胚系 TP53 R72P 和 MDM2 SNP309 变异与特定乳腺癌肿瘤亚组生存的相关性。
Breast Cancer Res Treat. 2011 Nov;130(2):599-608. doi: 10.1007/s10549-011-1615-y. Epub 2011 Jun 11.
7
Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.下一代“深度”测序检测 TP53 突变对雌激素受体阳性乳腺癌预后的意义。
Cancer Lett. 2014 Jan 1;342(1):19-26. doi: 10.1016/j.canlet.2013.08.028. Epub 2013 Aug 21.
8
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.TP53 基因突变状态预测的乳腺癌生存情况因治疗而异。
Breast Cancer Res. 2018 Oct 1;20(1):115. doi: 10.1186/s13058-018-1044-5.
9
Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.卵巢癌和乳腺癌中结构分组TP53突变患者的生存率。
Oncotarget. 2015 Jul 30;6(21):18641-52. doi: 10.18632/oncotarget.4080.
10
TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.TP53基因的突变与可手术切除的原发性乳腺癌患者接受基于蒽环类/环磷酰胺的新辅助化疗后较高的病理完全缓解率相关。
Int J Cancer. 2016 Jan 15;138(2):489-96. doi: 10.1002/ijc.29715. Epub 2015 Aug 13.
引用本文的文献
1
Chemical Complementarity of Blood-Sourced, Breast Cancer-Related TCR CDR3s and the CMV UL29 and IE1 Antigens is Associated with Worse Overall Survival.血液来源的、与乳腺癌相关的TCR CDR3与巨细胞病毒UL29和IE1抗原的化学互补性与较差的总生存期相关。
Biochem Genet. 2024 Oct 2. doi: 10.1007/s10528-024-10934-y.
2
Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.肿瘤驻留 T 细胞受体 CDR3 与肾酶 1 的化学互补性与黑色素瘤患者生存率的提高相关。
Oncotarget. 2024 Aug 5;15:550-561. doi: 10.18632/oncotarget.28633.
3
An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.癌症睾丸抗原DDX53作为潜在的早期食管癌抗原的免疫信息学评估
Oncoscience. 2023 Nov 10;10:59-66. doi: 10.18632/oncoscience.590. eCollection 2023.
4
Exploiting big data survival information to unify risk-stratification related, adaptive immune receptor parameters for multiple myeloma.利用大数据生存信息统一多发性骨髓瘤相关的风险分层、适应性免疫受体参数。
Genes Immun. 2023 Aug;24(4):194-199. doi: 10.1038/s41435-023-00212-z. Epub 2023 Jul 13.
5
IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.IGL CDR3 亲水性与抗原化学互补性与肺腺癌无病生存期延长相关：对性别差异的影响。
Biochem Genet. 2024 Feb;62(1):530-546. doi: 10.1007/s10528-023-10437-2. Epub 2023 Jul 1.
6
Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression.乳腺癌驻留T细胞受体CDR3结构域与癌症抗原ARMC3的化学互补性与更高的生存率和颗粒酶表达水平相关。
Cancer Inform. 2023 Jun 1;22:11769351231177269. doi: 10.1177/11769351231177269. eCollection 2023.
7
A Bioinformatics Assessment Indicating Better Outcomes With Breast Cancer Resident, Immunoglobulin CDR3-MMP2 Binding.一种生物信息学评估表明，乳腺癌患者中，与免疫球蛋白 CDR3-MMP2 结合的情况与更好的预后相关。
Cancer Genomics Proteomics. 2023 May-Jun;20(3):239-246. doi: 10.21873/cgp.20378.
8
Adaptive immune receptor features related to breast cancer tissue in Kenyan patients: high immunoglobulin gene expression and high levels of gamma-delta T-cells.肯尼亚患者乳腺癌组织中的适应性免疫受体特征：免疫球蛋白基因表达高和γ-δ T 细胞水平高。
Breast Cancer Res Treat. 2023 May;199(1):207-214. doi: 10.1007/s10549-023-06897-0. Epub 2023 Mar 8.
9
Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.通过血液样本可评估的 T 细胞受体 CDR3-肿瘤突变组芳香性因子的描绘，有助于在膀胱癌中建立生存差异。
J Cancer Res Clin Oncol. 2023 Jul;149(8):4359-4366. doi: 10.1007/s00432-022-04339-w. Epub 2022 Sep 13.
10
Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.保留序列信息的免疫受体CDR3化学特征在反映生存差异方面非常有效：一项泛癌分析。
Biomed Rep. 2022 Jun 9;17(2):68. doi: 10.3892/br.2022.1551. eCollection 2022 Aug.
Zotero 插件